{"answer":{"query":"cosentyx","resolved_as":"name","packages":7,"applications":["BLA125504","BLA761349"],"identity":{"application_numbers":["BLA125504","BLA761349"],"marketing_categories":["BLA"],"labelers":[{"text":"NOVARTIS PHARMACEUTICALS CORPORATION","untrusted":true}],"dosage_forms":[{"text":"INJECTION","untrusted":true},{"text":"INJECTION, SOLUTION, CONCENTRATE","untrusted":true}],"marketing_start":{"earliest":"2015-01-21","latest":"2023-10-06","packages_with_a_start_date":7}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":7,"negotiated_price_ends":null,"rows":[{"ndc":"00078063941","name":{"text":"COSENTYX SYRINGE 150MG/ML 2 SENSOREADY","untrusted":true},"class":"B","nadac_per_unit":3945.94,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078063968","name":{"text":"COSENTYX SYRINGE 150MG/ML SENSOREADYPEN","untrusted":true},"class":"B","nadac_per_unit":7858.47545,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078063997","name":{"text":"COSENTYX SYRINGE 150MG/ML","untrusted":true},"class":"B","nadac_per_unit":7887.958,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078063998","name":{"text":"COSENTYX SYRINGE 150MG/ML 2","untrusted":true},"class":"B","nadac_per_unit":3929.4865,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078105697","name":{"text":"COSENTYX SYRINGE 75MG/0.5ML","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078107068","name":{"text":"COSENTYX UNOREADY PEN 300MG/2ML","untrusted":true},"class":"B","nadac_per_unit":4088.58918,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078116861","name":{"text":"COSENTYX VIAL 125MG/5ML","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"label_history":{"events_total":35,"non_cmc_events":34,"counts_by_class":{"LABELING":19,"EFFICACY":15},"cmc_events":1,"recent_non_cmc_events":[{"application":"BLA125504","submission_no":99,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-10-15","documents":[{"type":"Label","date":"2026-10-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s099lbl.pdf","untrusted":true}}],"fact_id":"72351fb52eeae050730c33af"},{"application":"BLA761349","submission_no":13,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-10-15","documents":[{"type":"Letter","date":"2026-10-16","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761349Orig1s013;125504Orig1s099ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-10-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761349s013lbl.pdf","untrusted":true}}],"fact_id":"4647b3d16db6edd5509f65c5"},{"application":"BLA125504","submission_no":98,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-04-17","documents":[{"type":"Letter","date":"2026-04-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/125504Orig1s098;761349s012ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-04-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s098lbl.pdf","untrusted":true}}],"fact_id":"3b25591a248a28133eb643cb"},{"application":"BLA125504","submission_no":97,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-04-17","documents":[{"type":"Letter","date":"2026-04-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/125504s097;761349s011ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-04-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s097lbl.pdf","untrusted":true}}],"fact_id":"f30c3af0f0542efc8cc6cd37"},{"application":"BLA761349","submission_no":12,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-04-17","documents":[{"type":"Letter","date":"2026-04-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/125504Orig1s098;761349s012ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-08-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761349s012lbl.pdf","untrusted":true}}],"fact_id":"76f899f184c7552901bb44b6"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":2,"te_code_counts":{"TBD":1,"NOT_PROVIDED":1},"marketing_status_counts":{"Prescription":2},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"BLA125504","product_no":"001","te_code":"TBD","marketing_status":"Prescription","drug_name":{"text":"COSENTYX","untrusted":true},"form":{"text":"INJECTABLE;INJECTION","untrusted":true},"strength":{"text":"150MG/ML","untrusted":true}},{"application":"BLA761349","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"COSENTYX","untrusted":true},"form":{"text":"INJECTABLE;INJECTION","untrusted":true},"strength":{"text":"150MG","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class II":1},"packages_of_these_applications":7,"most_recent":[{"recall_number":"D-0742-2018","classification":"Class II","status":"Terminated","report_date":"2018-05-16","recall_initiated":"2018-04-03","recalling_firm":{"text":"Kroger Specialty Pharmacy, Inc.","untrusted":true},"reason":{"text":"Lack of Processing Controls.","untrusted":true},"packages_named":1,"fact_id":"cc18340adf5da57275cd3ce6"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"SECUKINUMAB","untrusted":true},"recruiting_interventional_count":11,"not_yet_recruiting_count":10,"by_phase":{"PHASE1":2,"PHASE4":5,"NA":3,"PHASE2":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT07237594","title":{"text":"IL-17 Blockade to Decrease irAEs (REPLAY)","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Duke University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2026-03-12","link":{"text":"https://clinicaltrials.gov/study/NCT07237594","untrusted":true}},{"nct_id":"NCT04638647","title":{"text":"Secukinumab Open Label Roll-over Extension Protocol","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Novartis Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-13","start_date":"2020-12-22","link":{"text":"https://clinicaltrials.gov/study/NCT04638647","untrusted":true}},{"nct_id":"NCT06751238","title":{"text":"Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Novartis Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-13","start_date":"2025-09-24","link":{"text":"https://clinicaltrials.gov/study/NCT06751238","untrusted":true}},{"nct_id":"NCT07489573","title":{"text":"Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Novartis Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-09","start_date":"2026-06-01","link":{"text":"https://clinicaltrials.gov/study/NCT07489573","untrusted":true}},{"nct_id":"NCT06399432","title":{"text":"Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors","untrusted":true},"phase":["NA"],"sponsor":{"text":"University Hospitals Cleveland Medical Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-04","start_date":"2022-10-18","link":{"text":"https://clinicaltrials.gov/study/NCT06399432","untrusted":true}}],"fact_id":"5c69ae3474dd671eed74e706"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Novartis Patient Assistance Foundation","untrusted":true},"type":"manufacturer","url":"https://pap.novartis.com/","status":{"state":"limited","effective":"2026-07-27","applies_to":{"text":"Novartis Patient Assistance Foundation applicants who applied on or after July 27, 2026","untrusted":true},"detail":{"text":"The Novartis Patient Assistance Foundation page states that for patients who applied for NPAF support on or after July 27, 2026, a new Patient Enrollment Portal is used: approved patients are encouraged to use it to re-fill medication, and patients told their application is missing information are encouraged to upload documents through it. The page lists no end date.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://pap.novartis.com/","proof_state":"verified"},"needs_status_check":true,"has_offer":false}],"manufacturer_offers":[{"program":"cosentyx-bridge-program-free-supply","kind":"free_trial","price_figures":{"freeSupplyUpToYears":2},"conditions":{"text":"The page states the Bridge Program applies to COSENTYX Subcutaneous Injection only, for patients with private insurance and a valid prescription whose prior authorization or exception was denied, requires an appeal of the denial within the first 90 days of enrollment, and lasts up to 2 years or until insurance approval, whichever is earlier.","untrusted":true},"limited_time":false,"expires_note":null,"stated_end_date":null,"expired":false,"detail":{"text":"The Cosentyx support page states a Bridge Program (Covered Until You Are Covered) that can provide up to 2 years of Cosentyx Subcutaneous Injection for free while coverage is sought, or until insurance approval if earlier, with conditions stated on the page.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://www.cosentyx.com/all/savings-support/novartis-patient-support","proof_state":"verified","fact_id":"3f0a298ce6598015dcbffa5c"}],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Secukinumab","untrusted":true},"brand":{"text":"Cosentyx","untrusted":true}},"latest_year":2024,"series":[{"year":2024,"gross_spending_usd":1133518.79,"claims":258,"beneficiaries":60,"average_spending_per_claim_usd":4393.4836822,"fact_id":"7151ff19bfb85851c968943f"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"biologic_status":{"products":[{"application":"BLA125504","status":"Reference","name":{"text":"Cosentyx","untrusted":true},"proper_name":{"text":"secukinumab","untrusted":true},"license_status":"Licensed; Voluntarily Revoked","approval_date":"2015-01-21","reference_product":null,"interchangeable_date":null,"biosimilars_listed":0,"interchangeables_listed":0,"biosimilars":[],"interchangeables":[],"purple_book_version":"purplebook-2026-10","read_on":"2026-11-07T07:33:31.186Z","fact_id":"9eadd060278de00647a35dba"},{"application":"BLA761349","status":"Reference","name":{"text":"Cosentyx","untrusted":true},"proper_name":{"text":"secukinumab","untrusted":true},"license_status":"Licensed","approval_date":"2023-10-06","reference_product":null,"interchangeable_date":null,"biosimilars_listed":0,"interchangeables_listed":0,"biosimilars":[],"interchangeables":[],"purple_book_version":"purplebook-2026-10","read_on":"2026-11-07T07:33:31.186Z","fact_id":"cdf68b6fb7ebd83d1ee609c9"}],"reading":"what the FDA Purple Book lists on its read date, a record and not a forecast of launch or substitution"},"payment_limit":{"codes":[{"hcpcs":"J3247","quarter":"2026Q4","effective":"October 1, 2026 through December 31, 2026","payment_limit_usd":18.131,"dosage_descriptor":{"text":"1 MG","untrusted":true},"packages_matched":1,"read_on":"2026-11-07T07:31:28.000Z","source_url":{"text":"https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files","untrusted":true},"fact_id":"fb6eb82177d15f615f7366f9"}],"codes_total":1,"meaning":"a Medicare Part B payment ceiling for providers billing a HCPCS code, per dosage descriptor unit; not a price a patient pays, and the presence of a code does not indicate that Medicare covers a product"},"orphan_designation":{"ingredients":[{"ingredient":{"text":"secukinumab","untrusted":true},"designation_count":1,"approved_count":0,"recent":[{"designated":"2010-03-26","use":{"text":"Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression","untrusted":true},"status":"Designated/Designation Withdrawn or Revoked","sponsor":{"text":"Novartis Pharmaceutical Corporation","untrusted":true},"approved":false}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"9466aa796d27fbadf0904f21"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":26,"all_states_medicaid_reimbursed_usd":50165067.27,"all_states_medicaid_paid_prescriptions":6050,"top_states":[{"state":"OH","medicaid_paid_prescriptions":2143,"medicaid_reimbursed_usd":21192403.1,"total_reimbursed_usd":22021521.51,"packages":3,"covers":"fee_for_service_only","fact_id":"9039c6fca914cb7a86f9a932"},{"state":"LA","medicaid_paid_prescriptions":1007,"medicaid_reimbursed_usd":10856150.28,"total_reimbursed_usd":11113853.38,"packages":1,"covers":"fee_for_service_only","fact_id":"351a5963e5c52378d58da449"},{"state":"MO","medicaid_paid_prescriptions":434,"medicaid_reimbursed_usd":4907725.49,"total_reimbursed_usd":4922739.43,"packages":2,"covers":"all_record_types","fact_id":"89eeb9ee99f5b50588784e59"},{"state":"UT","medicaid_paid_prescriptions":210,"medicaid_reimbursed_usd":2194196.65,"total_reimbursed_usd":2207704.67,"packages":1,"covers":"all_record_types","fact_id":"601d82f4dcd7888709305483"},{"state":"SD","medicaid_paid_prescriptions":137,"medicaid_reimbursed_usd":1482837.99,"total_reimbursed_usd":1482837.99,"packages":1,"covers":"all_record_types","fact_id":"4ab805f598e907d97a9dc71b"},{"state":"VT","medicaid_paid_prescriptions":115,"medicaid_reimbursed_usd":1233829.16,"total_reimbursed_usd":1233829.16,"packages":1,"covers":"all_record_types","fact_id":"d64009b10363713111365b8e"},{"state":"IL","medicaid_paid_prescriptions":135,"medicaid_reimbursed_usd":1145280.33,"total_reimbursed_usd":1145280.33,"packages":1,"covers":"all_record_types","fact_id":"09a229fbf57fb168aff4db7d"},{"state":"DC","medicaid_paid_prescriptions":76,"medicaid_reimbursed_usd":1052443.78,"total_reimbursed_usd":1128788.78,"packages":1,"covers":"all_record_types","fact_id":"ee3ba5ac0096b0d7dea6092e"},{"state":"MN","medicaid_paid_prescriptions":213,"medicaid_reimbursed_usd":832466.59,"total_reimbursed_usd":916036.37,"packages":2,"covers":"fee_for_service_only","fact_id":"5305a35883d101f87fbb92f7"},{"state":"NV","medicaid_paid_prescriptions":77,"medicaid_reimbursed_usd":563919.97,"total_reimbursed_usd":563919.97,"packages":1,"covers":"fee_for_service_only","fact_id":"12e1eda9cdad1a75df6cd259"}],"unlabelled_state_code_xx":null,"built_from_facts":30,"facts_fee_for_service_only":11,"older_year_facts_not_used":180,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"3f25d2ca61873ac6e93e0766","field":"ndc.listing","entity":"ndc:00078063941"},{"fact_id":"fff34c68c6a18df157e66aaa","field":"ndc.listing","entity":"ndc:00078063968"},{"fact_id":"6882deaa42322d871c1958c0","field":"ndc.listing","entity":"ndc:00078063997"},{"fact_id":"72351fb52eeae050730c33af","field":"drug.label_event","entity":"application:BLA125504"},{"fact_id":"4647b3d16db6edd5509f65c5","field":"drug.label_event","entity":"application:BLA761349"},{"fact_id":"3b25591a248a28133eb643cb","field":"drug.label_event","entity":"application:BLA125504"},{"fact_id":"f30c3af0f0542efc8cc6cd37","field":"drug.label_event","entity":"application:BLA125504"},{"fact_id":"76f899f184c7552901bb44b6","field":"drug.label_event","entity":"application:BLA761349"},{"fact_id":"3d1b415d2ebcaa3c7f279868","field":"drug.te_code","entity":"application:BLA125504"},{"fact_id":"7580d880b2ad3a45c9ab5c79","field":"drug.marketing_status","entity":"application:BLA125504"},{"fact_id":"4d396357a01eb5a1e1fe9ebc","field":"drug.marketing_status","entity":"application:BLA761349"},{"fact_id":"cc18340adf5da57275cd3ce6","field":"ndc.recall","entity":"ndc:00078063998"},{"fact_id":"5c69ae3474dd671eed74e706","field":"drug.trial_access","entity":"drug:secukinumab"},{"fact_id":"04e762d41a1aeb9b84c84d80","field":"program.status","entity":"program:cosentyx-patient-assistance"},{"fact_id":"3f0a298ce6598015dcbffa5c","field":"program.offer","entity":"program:cosentyx-bridge-program-free-supply"},{"fact_id":"7151ff19bfb85851c968943f","field":"drug.partd_spending","entity":"drug:secukinumab|cosentyx"},{"fact_id":"9eadd060278de00647a35dba","field":"drug.biologic_status","entity":"application:BLA125504"},{"fact_id":"cdf68b6fb7ebd83d1ee609c9","field":"drug.biologic_status","entity":"application:BLA761349"},{"fact_id":"fb6eb82177d15f615f7366f9","field":"drug.asp_price","entity":"hcpcs:J3247"},{"fact_id":"9466aa796d27fbadf0904f21","field":"drug.orphan_designation","entity":"drug:secukinumab"},{"fact_id":"9039c6fca914cb7a86f9a932","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078107068:OH"},{"fact_id":"351a5963e5c52378d58da449","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078107068:LA"},{"fact_id":"89eeb9ee99f5b50588784e59","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078107068:MO"},{"fact_id":"601d82f4dcd7888709305483","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078107068:UT"},{"fact_id":"4ab805f598e907d97a9dc71b","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078107068:SD"},{"fact_id":"d64009b10363713111365b8e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078107068:VT"},{"fact_id":"09a229fbf57fb168aff4db7d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078063997:IL"},{"fact_id":"ee3ba5ac0096b0d7dea6092e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078063968:DC"},{"fact_id":"5305a35883d101f87fbb92f7","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078063997:MN"},{"fact_id":"12e1eda9cdad1a75df6cd259","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078063968:NV"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"generic_entry:BLA125504","reason":"no generic-entry fact for this application: no patent or exclusivity is listed for it in the Orange Book edition read, so no date is stated"},{"code":"NO_DATA","field":"generic_entry:BLA761349","reason":"no generic-entry fact for this application: no patent or exclusivity is listed for it in the Orange Book edition read, so no date is stated"},{"code":"NO_DATA","field":"generic_entry","reason":"no application of this drug has a generic-entry fact; no date is stated"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}